Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 273 Carcinoma, Non-Small-Cell Lung 224 Prostatic Neoplasms 181 Neoplasms 174 Lung Neoplasms 137 Multiple Myeloma 136 Neoplasm Metastasis 101 Colorectal Neoplasms 100 Melanoma 87 Ovarian Neoplasms 80 Leukemia, Myeloid, Acute 74 Pancreatic Neoplasms 73 Lymphoma 69 Carcinoma, Renal Cell 65 Leukemia, Lymphocytic, Chronic, B-Cell 64 Brain Neoplasms 63 Lymphoma, Non-Hodgkin 62 Squamous Cell Carcinoma of Head and Neck 61 Recurrence 56 Urinary Bladder Neoplasms 55 Hematologic Neoplasms 55 Carcinoma, Hepatocellular 54 Head and Neck Neoplasms 53 Triple Negative Breast Neoplasms 51 Lymphoma, Follicular 48 Glioblastoma 48 Endometrial Neoplasms 47 Uterine Cervical Neoplasms 45 Precursor Cell Lymphoblastic Leukemia-Lymphoma 45 Sarcoma 44

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × mCRPC × 90 days × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡